Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study comparing subcutaneous versus intravenous frexalimab in adults with multiple sclerosis
CTR20260885Phase 3Active
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of frexalimab in multiple sclerosis (MS) (4 arms), sponsored by Sanofi. Started Jun 2026; status: active.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20260885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260885.